As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025.

Joining the consortium are Bristol Myers Squibb, COGNANO, Lambda, Novo Nordisk ... Design. Structure Therapeutics, headquartered in San Francisco, California, is a biotechnology company focused ...